# NUCB1

## Overview
NUCB1 is a gene that encodes the protein nucleobindin 1, a multifunctional calcium-binding protein involved in various cellular processes. Nucleobindin 1 is characterized by its multidomain structure, which includes EF-hand motifs crucial for calcium binding, a coiled-coil region, and a leucine zipper domain, facilitating its role as a calcium-regulated guanine nucleotide dissociation inhibitor (GDI) and in protein trafficking within the Golgi apparatus (Leung2019Nucleobindins; Kapoor2010Nucleobindin). The protein is implicated in the regulation of G protein signaling pathways and the trafficking of matrix metalloproteinases, impacting cellular signaling and extracellular matrix degradation (PachecoFernandez2020Nucleobindin1; Kapoor2010Nucleobindin). NUCB1's expression levels have clinical significance, being associated with various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases, highlighting its potential as a biomarker and therapeutic target (Ejtehadifar2023MetaAnalysis; BonitoOliva2017Nucleobindin).

## Structure
Nucleobindin 1 (NUCB1) is a multidomain protein with a complex molecular structure. It is a 55 kDa protein that includes several distinct sequence regions: an N-terminal signal peptide, a basic DNA-binding domain, two calcium-binding EF-hand motifs, a coiled-coil region with a leucine zipper domain, and a polyglutamine stretch (Leung2019Nucleobindins; Mikhaylina2023The; Kapoor2010Nucleobindin). The EF-hand motifs are crucial for calcium binding, inducing conformational changes that affect the protein's function (Leung2019Nucleobindins; Kapoor2010Nucleobindin). 

NUCB1 exists as a dimer in solution, facilitated by the C-terminal leucine zipper domain, and this dimerization is calcium-dependent (Kapoor2010Nucleobindin). The protein's structure is asymmetric, with an elongated C-terminal domain contributing to this asymmetry (Kapoor2010Nucleobindin). The EF-hand domain, described as a helix-loop-helix structure, is involved in calcium binding, with different affinities for each motif (Leung2019Nucleobindins). 

Post-translational modifications, such as phosphorylation, are noted to affect NUCB1's function, with specific sites conserved across species (Leung2019Nucleobindins). The protein's RNA-binding properties are distinct from its DNA-binding activity and are not dependent on calcium (Mikhaylina2023The).

## Function
Nucleobindin 1 (NUCB1) is a calcium-binding protein that plays a significant role in various cellular processes, particularly in the trafficking of matrix metalloproteinases (MMPs) within the Golgi apparatus. NUCB1 is crucial for the intra-Golgi transport of MMP2, facilitating its movement from the cis-Golgi to the trans-Golgi. This process is essential for the degradation of the extracellular matrix, impacting cell migration and tissue remodeling (PachecoFernandez2020Nucleobindin1). NUCB1's function in MMP trafficking is calcium-dependent, with its EF-hand motifs being critical for calcium binding, which in turn affects its interaction with MMP2 (PachecoFernandez2020Nucleobindin1).

In addition to its role in protein trafficking, NUCB1 acts as a calcium-regulated guanine nucleotide dissociation inhibitor (GDI) for the Gαi1 protein, modulating G protein signaling pathways. This function involves inhibiting the GDP release from Gαi1, thereby regulating downstream signaling events mediated by G protein-coupled receptors (GPCRs) (Kapoor2010Nucleobindin). NUCB1 is distributed across various cellular compartments, including the Golgi, nucleus, endoplasmic reticulum, and cytoplasm, highlighting its diverse roles in cellular signaling and function (Kapoor2010Nucleobindin).

## Clinical Significance
Alterations in the expression of the NUCB1 gene have been implicated in several diseases, particularly in cancer and autoimmune conditions. In diffuse large B-cell lymphoma (DLBCL), NUCB1 is significantly up-regulated, especially in the activated B-cell-like (ABC) subtype, and is associated with poor overall survival, suggesting its potential as a prognostic biomarker (Ejtehadifar2023MetaAnalysis). High NUCB1 expression is also linked to shorter progression-free survival and overall survival in colorectal cancer (Ejtehadifar2023MetaAnalysis).

In pancreatic ductal adenocarcinoma (PDAC), low NUCB1 expression correlates with poor prognosis, while its overexpression suppresses tumor growth and enhances the effects of chemotherapy, indicating its role in tumor progression and drug response (Hua2021NUCB1). NUCB1 is also involved in systemic lupus erythematosus (SLE), where elevated serum levels have been observed, potentially contributing to the disease's pathophysiology through interactions with microRNAs (Mikhaylina2023The).

NUCB1's role in neurodegenerative diseases is highlighted by its interaction with amyloid precursor protein (APP), where it inhibits amyloid aggregation, a process relevant to Alzheimer's disease (Leung2019Nucleobindins; BonitoOliva2017Nucleobindin). These findings underscore NUCB1's clinical significance in various pathological conditions.

## Interactions
Nucleobindin 1 (NUCB1) is involved in several protein interactions that are crucial for its function in cellular processes. NUCB1 acts as a calcium-regulated guanine nucleotide dissociation inhibitor (GDI) for the G protein subunit Gαi1. It binds to Gαi1 in its GDP-bound form, inhibiting nucleotide exchange and thus affecting Gαi1 activation. This interaction is calcium-dependent and does not rely on the conventional GoLoco motif, indicating a unique mechanism of GDI activity (Kapoor2010Nucleobindin).

NUCB1 also plays a role in the trafficking of matrix metalloproteinases (MMPs), specifically MMP2 and MT1-MMP, within the Golgi apparatus. It facilitates the intra-Golgi trafficking of these MMPs, which is essential for extracellular matrix degradation. The interaction between NUCB1 and MMP2 is calcium-dependent, and the absence of NUCB1 results in delayed MMP2 trafficking (PachecoFernandez2020Nucleobindin1).

Additionally, an engineered form of NUCB1, mtNUCB1, has been shown to interact with amyloid proteins, such as Aβ 42, inhibiting their fibrillization. This interaction stabilizes protofibrils and prevents further aggregation, suggesting a potential therapeutic role in amyloid-related diseases (BonitoOliva2017Nucleobindin).


## References


[1. (PachecoFernandez2020Nucleobindin1) Natalia Pacheco-Fernandez, Mehrshad Pakdel, Birgit Blank, Ismael Sanchez-Gonzalez, Kathrin Weber, Mai Ly Tran, Tobias Karl-Heinz Hecht, Renate Gautsch, Gisela Beck, Franck Perez, Angelika Hausser, Stefan Linder, and Julia von Blume. Nucleobindin-1 regulates ecm degradation by promoting intra-golgi trafficking of mmps. Journal of Cell Biology, June 2020. URL: http://dx.doi.org/10.1083/jcb.201907058, doi:10.1083/jcb.201907058. This article has 26 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1083/jcb.201907058)

[2. (Kapoor2010Nucleobindin) Neeraj Kapoor, Ruchi Gupta, Santosh T. Menon, Ewa Folta-Stogniew, Daniel P. Raleigh, and Thomas P. Sakmar. Nucleobindin 1 is a calcium-regulated guanine nucleotide dissociation inhibitor of gαi1. Journal of Biological Chemistry, 285(41):31647–31660, October 2010. URL: http://dx.doi.org/10.1074/jbc.M110.148429, doi:10.1074/jbc.m110.148429. This article has 45 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M110.148429)

[3. (Leung2019Nucleobindins) Adelaine Kwun-Wai Leung, Naresh Ramesh, Christine Vogel, and Suraj Unniappan. Nucleobindins and encoded peptides: From cell signaling to physiology, pages 91–133. Elsevier, 2019. URL: http://dx.doi.org/10.1016/bs.apcsb.2019.02.001, doi:10.1016/bs.apcsb.2019.02.001. This article has 19 citations.](https://doi.org/10.1016/bs.apcsb.2019.02.001)

[4. (Ejtehadifar2023MetaAnalysis) Mostafa Ejtehadifar, Sara Zahedi, Paula Gameiro, José Cabeçadas, Maria Gomes da Silva, Hans C. Beck, Ana Sofia Carvalho, and Rune Matthiesen. Meta-analysis of ms-based proteomics studies indicates interferon regulatory factor 4 and nucleobindin1 as potential prognostic and drug resistance biomarkers in diffuse large b cell lymphoma. Cells, 12(1):196, January 2023. URL: http://dx.doi.org/10.3390/cells12010196, doi:10.3390/cells12010196. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells12010196)

[5. (Hua2021NUCB1) Yong-Qiang Hua, Ke Zhang, Jie Sheng, Zhou-Yu Ning, Ye Li, Wei-dong Shi, and Lu-Ming Liu. Nucb1 suppresses growth and shows additive effects with gemcitabine in pancreatic ductal adenocarcinoma via the unfolded protein response. Frontiers in Cell and Developmental Biology, March 2021. URL: http://dx.doi.org/10.3389/fcell.2021.641836, doi:10.3389/fcell.2021.641836. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2021.641836)

[6. (Mikhaylina2023The) Alisa Mikhaylina, Arina Svoeglazova, Elena Stolboushkina, Svetlana Tishchenko, and Olga Kostareva. The rna-binding and rna-melting activities of the multifunctional protein nucleobindin 1. International Journal of Molecular Sciences, 24(7):6193, March 2023. URL: http://dx.doi.org/10.3390/ijms24076193, doi:10.3390/ijms24076193. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24076193)

[7. (BonitoOliva2017Nucleobindin) Alessandra Bonito-Oliva, Shahar Barbash, Thomas P. Sakmar, and W Vallen Graham. Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization. Scientific Reports, February 2017. URL: http://dx.doi.org/10.1038/srep42880, doi:10.1038/srep42880. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep42880)